Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGAV | P06756 | 2/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768020 | 0.96 | FOLH1 (0.59) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL631840 | 0.96 | FOLH1 (0.59) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL5145708 | 0.96 | FOLH1 (0.59) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL29790888 | 0.95 | CPB1 (0.61) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL3381295 | 0.95 | CTSL (0.64) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL6271116 | 0.95 | CTSL (0.53) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| Water SCHEMBL7274005 | 0.94 | FOLH1 (0.58) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| Hydrochloric Acid SCHEMBL333888 | 0.94 | FOLH1 (0.58) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| Bromide SCHEMBL9221277 | 0.94 | FOLH1 (0.58) | CTSLFOLH1SIRT2SIRT1ITGB3 | |
| Hydrochloric Acid SCHEMBL333889 | 0.94 | FOLH1 (0.58) | CTSLFOLH1SIRT2SIRT1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463445-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | DORPHAN S A (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250269054-A1 | NANOPARTICLE DRUG CONJUGATES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | DORPHAN S.A. (CH) | 2025-03-06 | — | — | US | disclosed |
| EP-4463445-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | Dorphan S.A. (CH) | 2024-11-20 | — | — | EP | disclosed |
| CN-118786120-A | Compounds and their use for the treatment of diseases associated with impaired beta-galactosidase activity | 多尔潘股份公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| WO-2023135480-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED β-GALACTOSIDASE ACTIVITY | DORPHAN SA (CH) | 2023-07-20 | — | — | WO | disclosed |
| US-20220257604-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | US | disclosed |
| US-4229528-A | Fluorescence method for enzyme analysis which couples aromatic amines with aromatic aldehydes | SMITH ROBERT E | 1980-10-21 | — | — | US | disclosed |
| US-4155916-A | Fluorescence method for enzyme analysis which couples aromatic amines with aromatic aldehydes | DOLBEARE FRANK A | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | MAN2B1, MANBA, GALC | CTSL 75/4885FOLH1 635/4885SIRT2 1205/4885 |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | CTRL, SERPINB1, PRSS1 | CTSL 16/4885FOLH1 172/4885SIRT2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.